Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib

Phase 2positivedabogratinibPositive

AI Analysis

Summary

Tyra Biosciences reported positive Phase 2 SURF302 results for dabogratinib in low-grade intermediate-risk non-muscle-invasive bladder cancer, demonstrating favorable safety and tolerability supporting its potential as the first oral innovation for first-line treatment in this indication.

Clinical Trial Data

Phase

Phase 2

Primary Endpoint

Met

Outcome Details

Favorable safety and tolerability results supporting chronic dosing potential; no clinically significant hyperphosphatemia, nail toxicity, or ocular toxicity; low frequency of adverse events

Importance:7/10

Sentiment:

0.75

Phase 2 dataoral drug candidatefirst-line treatmentbladder cancersafety profiletolerability

Related Companies

$TRAX

Read the original article

Published by PR Newswire Biotech on September 9, 2026 11:00 AM

Read Original